Archive
551 articles, sorted by publication time.
Fibrolamellar hepatocellular carcinoma has long made it difficult for immune checkpoint drugs to take effect; new research points to “T-cell exclusion” in the tumor microenvironment and, in patient tumor slices, finds that the FDA-approved drug AMD3100 may be able to remove this barrier.
This is not news sufficient to declare a drug breakthrough, but a signal: AI drug development is shifting from demonstrating platform capabilities to pharmaceutical companies outsourcing and validating early biological risk in stages.
As new drugs for neuropsychiatric diseases move from concept toward the clinic, the real bottleneck is not only molecular design, but also whether medicines for human studies can be produced stably and in compliance with regulations. The partnership between BetterLife and Syner-G shows that small biotech companies are pushing R&D risk into manufacturing and quality control.
Whether AI can shorten new drug development will not be proven by computing scale alone; Recursion’s next hurdle is to move the hypotheses proposed by its models through clinical trials, partner validation, and regulatory review.
HHS and the FDA are focusing reform on the narrow bottlenecks before and after first-in-human trials: clarifying regulatory expectations earlier, preserving flexibility in trial design, and using remote tools and real-world data to broaden participation. The balance of this acceleration effort will depend on whether speed can advance alongside participant protection.
The new collaboration between Insilico and SK Biopharmaceuticals puts generative AI at the front end of target interpretation and molecular design; the deal ceiling is large, but what can be determined for now is that responsibility in drug development is being divided up anew.
A market article framed around hedge fund holdings prompts a fresh look at Tempus AI’s position: it is not a typical AI drug company that directly advances molecules into the clinic, but one that turns oncology genomics, clinical data, and analytics tools into R&D infrastructure.
As drug development shifts its focus from polished algorithms to data closer to patients, the value of AI is also being redefined: it must deliver answers across human biology, validation workflows, and regulatory trust.
Hedge funds are buying AI drug discovery stocks, reflecting that capital markets are still willing to bet on faster, cheaper new drug development. But from a model finding a clue to patients truly benefiting, the path remains one lengthened by experiments, clinical trials, and regulation.
A vaccine whose active ingredient was designed through computer modeling has crossed an early safety threshold in 39 volunteers; it has not yet shown it can prevent infection, but it moves the idea of “preparing in advance for the next viral spillover” into clinical testing.
A partnership advanced by Abu Dhabi’s health authority and Biocom California shows that the Gulf city is extending its biotech ambitions beyond capital and infrastructure into industry networks and R&D connections.
Mabwell’s T-cell engager targeting LILRB4 and CD3 has received clinical trial approval in China; this is not an answer on efficacy, but it does bring a blood cancer target with immunosuppressive properties into formal human testing.